These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31128336)

  • 1. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
    Dreesen E; Baert F; Laharie D; Bossuyt P; Bouhnik Y; Buisson A; Lambrecht G; Louis E; Oldenburg B; Pariente B; Pierik M; van der Woude CJ; D'Haens G; Vermeire S; Gils A
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):637-646.e11. PubMed ID: 31128336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
    Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
    World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
    Bossuyt P; Dreesen E; Rimola J; Devuysere S; De Bruecker Y; Vanslembrouck R; Laurent V; Zappa M; Savoye-Collet C; Pariente B; Filippi J; Baert F; D'Haens G; Laharie D; Peyrin-Biroulet L; Vermeire S;
    Clin Gastroenterol Hepatol; 2021 May; 19(5):947-954.e2. PubMed ID: 32360982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
    Colman RJ; Tsai YT; Jackson K; Boyle BM; Noe JD; Hyams JS; D'Haens GRAM; van Limbergen J; Rosen MJ; Denson LA; Minar P
    Inflamm Bowel Dis; 2021 Jun; 27(7):1045-1051. PubMed ID: 32944769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Rivière P; D'Haens G; Peyrin-Biroulet L; Baert F; Lambrecht G; Pariente B; Bossuyt P; Buisson A; Oldenburg B; Vermeire S; Laharie D
    Am J Gastroenterol; 2021 Jan; 116(1):134-141. PubMed ID: 33177349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
    Sorrentino D; Marino M; Dassopoulos T; Zarifi D; Del Bianco T
    PLoS One; 2015; 10(12):e0144900. PubMed ID: 26670274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.
    Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
    Inflamm Bowel Dis; 2018 Sep; 24(10):2266-2271. PubMed ID: 29718327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA.
    Minar PP; Colman RJ; Zhang N; Mizuno T; Vinks AA
    BMJ Open; 2024 Mar; 14(3):e077193. PubMed ID: 38531570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Hanžel J; Koželj M; Špes Hlastec A; Kurent T; Sever N; Zdovc J; Smrekar N; Novak G; Štabuc B; Grabnar I; Drobne D
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e831-e836. PubMed ID: 34402470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
    Reinisch W; Panaccione R; Bossuyt P; Baert F; Armuzzi A; Hébuterne X; Travis S; Danese S; Sandborn WJ; Schreiber S; Berg S; Zhou Q; Kligys K; Neimark E; Suleiman AA; D'Haens G; Colombel JF
    Inflamm Bowel Dis; 2020 Sep; 26(10):1562-1571. PubMed ID: 32105310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab.
    D'Arcangelo G; Oliva S; Dilillo A; Viola F; Civitelli F; Isoldi S; Cucchiara S; Aloi M
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):841-846. PubMed ID: 30633110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn's Disease.
    Lee YM; Kim ES; Choi S; Jang HJ; Kim YB; Choi SY; Choe BH; Kang B
    Gut Liver; 2024 May; 18(3):498-508. PubMed ID: 38013474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease.
    Brand EC; Elias SG; Minderhoud IM; van der Veen JJ; Baert FJ; Laharie D; Bossuyt P; Bouhnik Y; Buisson A; Lambrecht G; Louis E; Pariente B; Pierik MJ; van der Woude CJ; D'Haens GRAM; Vermeire S; Oldenburg B;
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1704-1718. PubMed ID: 31881273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.